Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.) Patents (Class 424/94.63)
Metalloproteinases (3.4.24) (e.g., collagenase, snake venom zinc proteinase, etc.) (Class 424/94.67)
-
Publication number: 20130273027Abstract: Mutant enzymes and methods of use thereof are provided.Type: ApplicationFiled: March 13, 2013Publication date: October 17, 2013Inventors: Craig Leach, Michael Eddins, David Stemer, Benjamin Nicholson
-
Publication number: 20130273116Abstract: The present invention also relates to an anti-fouling composition comprising one or more aerogels. In one embodiment the aerogel encapsulate one or more bioactive agents. The one or more encapsulated bioactive agents can in one preferred embodiment be released from the aerogel over time. In one embodiment the encapsulated bioactive agents comprise one or more enzymes. In one preferred embodiment the anti-fouling composition comprising one or more aerogels is a coating composition.Type: ApplicationFiled: February 8, 2013Publication date: October 17, 2013Inventors: COATZYME APS, ENPRO APS, CISMI
-
Patent number: 8551467Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: GrantFiled: July 2, 2012Date of Patent: October 8, 2013Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20130253382Abstract: Methods and compositions for the treatment of biofilms and/or the inhibition of biofilm formation. In one embodiment, a biofilm is treated and/or biofilm formation is inhibited by a method comprising contacting a biofilm or a surface with a bifunctional ligand comprising a quorum-sensing-peptide-binding region and a protease-binding region, whereby the biofilm is treated and/or biofilm formation on the surface is inhibited.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Inventors: RODOLFO ALARCON, Amy K. McNulty
-
Patent number: 8540983Abstract: The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.Type: GrantFiled: February 6, 2012Date of Patent: September 24, 2013Assignee: MediWound Ltd.Inventors: Marian Gorecki, Amir Toren
-
Publication number: 20130236444Abstract: A method for treating a patient with migraine headache includes administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form. The administration includes extramuscular injection of the neurotoxin to emerging nerve points including foraminal sites for enabling neurotoxin access to concentrated nerve bundles at exit points of the foramina.Type: ApplicationFiled: May 23, 2012Publication date: September 12, 2013Inventor: William J. BINDER
-
Publication number: 20130230598Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.Type: ApplicationFiled: February 20, 2013Publication date: September 5, 2013Applicant: LG LIFE SCIENCES, LTD., INC.Inventors: Myung-Jin KIM, Sun-Jin KIM, Oh-Ryong KWON
-
Patent number: 8524220Abstract: Bacteria which co-express protease inhibitors and protease sensitive therapeutic agents, which are surface displayed, secreted and/or released and result in their localized production and maintenance within a target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. Protease sensitivity may be further accomplished by engineering protease degradation sites within the therapeutic agents, further enhancing the inactivation outside of the target tissue while retaining activity within the target tissue through co-expression of a protease inhibitor. Novel chimeric proteins secreted by bacteria, including chimeric toxins targeted to neoplastic cells, tumor matrix cells and cells of the immune system, and combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described.Type: GrantFiled: February 9, 2011Date of Patent: September 3, 2013Inventor: David Gordon Bermudes
-
Patent number: 8524225Abstract: The present invention relates to a process for the proteolytic hydrolysis of a peptide or a polypeptide, said peptide or polypeptide comprising 4 to 40, preferably 5 to 35, amino acid residues and said peptide or polypeptide is not hydrolysable by subtilisin whereby said peptide or polypeptide is hydrolysed by a proline specific endo protease at a pH of 6.5 or lower, preferably 5.5 or lower and more preferably 5.0 or lower to hydrolyse said peptide or polypeptide.Type: GrantFiled: September 23, 2004Date of Patent: September 3, 2013Assignee: DSM IP Assets B.V.Inventors: Luppo Edens, Melissa Harvey, Robertus Antonius Mijndert Van Der Hoeven, Andre Leonardus De Roos
-
Publication number: 20130224172Abstract: Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same.Type: ApplicationFiled: January 3, 2013Publication date: August 29, 2013Applicant: CUREMARK, LLCInventor: CUREMARK, LLC
-
Publication number: 20130224178Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.Type: ApplicationFiled: February 15, 2013Publication date: August 29, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130224131Abstract: This invention relates to the use of 4-amidino benzylamine derivatives as cosmetic ingredients and to cosmetic compositions, as well as to non-therapeutic methods for the cosmetic treatment of the skin and the scalp. Said derivatives and compositions can be used as urokinase inhibitors to prevent and restore damage of the epidermal barrier. Barrier abnormalities and disruptions respectively are often the starting point of a dry skin state, of itching, of dandruff and of the perception of sensitive skin. These 4-amidino benzylamine derivatives can be used for topical skin and scalp care applications in form of creams, lotions, gels, shampoos and the like.Type: ApplicationFiled: February 12, 2013Publication date: August 29, 2013Applicant: DSM IP ASSETS B.V.Inventor: DSM IP ASSETS B.V.
-
Publication number: 20130224302Abstract: A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye.Type: ApplicationFiled: March 29, 2013Publication date: August 29, 2013Applicant: The Regents of the University of CaliforniaInventor: The Regents of the University of California
-
Patent number: 8518414Abstract: This invention relates to novel compositions of botulinum toxin that can be applied topically for various therapeutic, aesthetic and/or cosmetic purposes. The compositions may include botulinum toxin complexes, wherein the amounts of hemagglutinin, non-toxin non-hemagglutinin and/or exogenous albumin are selectively and independently reduced compared to conventional commercially available botulinum toxin. The compositions may further contain molecules that are not native to botulinum toxin and that bind non-covalently to the botulinum toxin complexes, thereby acting as skin-tropic “adhesion molecules” to improve the ability of the toxin complexes to adhere to and to penetrate the skin epithelium. The compositions have an improved safety profile compared to existing botulinum-containing compositions that are injected subcutaneously. Methods for the use of such compositions are also contemplated by this invention.Type: GrantFiled: November 16, 2006Date of Patent: August 27, 2013Assignee: Revance Therapeutics, Inc.Inventor: Jacob M. Waugh
-
Publication number: 20130209411Abstract: The invention relates to lactocepins and/or a functionally active fragment thereof for use in the prophylaxis and/or the treatment of a disease and to one or more lactocepin(s) and/or one or more functionally active fragment(s) thereof for use in the prophylaxis and/or treatment of IP-10-mediated inflammatory diseases.Type: ApplicationFiled: February 11, 2011Publication date: August 15, 2013Applicant: Technische Universitat MunchenInventors: Dirk Haller, Gabriele Hormannsperger
-
Patent number: 8506944Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: GrantFiled: October 23, 2009Date of Patent: August 13, 2013Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 8486390Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: GrantFiled: July 31, 2012Date of Patent: July 16, 2013Assignee: Curemark LLCInventor: Joan M. Fallon
-
Publication number: 20130177598Abstract: A pharmaceutical composition comprising protein micro and/or nanoparticles are provided. The particles have a predetermined geometric shape and a broadest dimension less than about 10 micrometers. The particles may further comprise active agents.Type: ApplicationFiled: February 27, 2008Publication date: July 11, 2013Applicant: The University of North Carolina at Chapel HillInventors: Joseph M. Desimone, Stephanie Gratton, Ji Guo, Jennifer Yvonne Kelly, Andrew James Murphy, Mary E Napier
-
Publication number: 20130171109Abstract: There are gluten-degrading enzymes found in Rothia species bacteria that are capable of breaking peptide bonds in -XPQ-, -QQP-, -PPF-, -LYP- and/or -PFP-containing peptides. These enzymes are acidic enzymes; they retain protease activity at acidic pH, eg., at 3.0, and have isoelectric points in a pH range of 2.0-7.0. Embodiments herein provide isolated enzyme compositions and probiotic compositions comprising at least one acidic gluten-degrading enzyme or a Rothia species bacteria. Also provided herein are methods of treatment of celiac disease or a related disorder, treatment of gluten-containing foodstuff, degrading and/or detoxifying gluten comprising the acidic gluten-degrading enzyme and/or compositions.Type: ApplicationFiled: July 7, 2011Publication date: July 4, 2013Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Eva J. Helmerhorst, Frank G. Oppenheim
-
Publication number: 20130171204Abstract: A soft extruded food composition containing probiotics, enzymes, and vitamins for wrapping medications, such as pills or tablets, for animal consumption. The flavor of the wrapped solid medication is masked by the food composition and thus becomes more palatable to the animal while providing additional health benefits in the form of probiotics, prebiotics, enzymes, and vitamins.Type: ApplicationFiled: December 28, 2012Publication date: July 4, 2013Applicant: VETS PLUS, INC.Inventor: Vets Plus, Inc.
-
Publication number: 20130166040Abstract: The invention provides reagents and method for replacing teeth lost to periodontitis and other diseases and disorders resulting in tooth loss, and provides materials and methods that result in replacement or reimplanted teeth that have a higher rate of stable, long-term implantation status. In a first aspect, the invention provides an implantable tooth, comprising a natural or artificial animal tooth having a microporous tooth root surface, wherein said tooth root surface comprises a plurality of periodontal ligament progenitor cells coating all or a portion of the tooth root. In particular embodiments, the tooth is a natural tooth, especially a human tooth. In alternative embodiments, the tooth is an artificial tooth. In particular embodiments, the tooth comprises a periodontal ligament progenitor cell coating that further comprises one or a plurality of extracellular matrix proteins. In a second aspect, the ivnention provides kits for preparing an implantable tooth.Type: ApplicationFiled: June 24, 2011Publication date: June 27, 2013Applicant: The Board of Trustee of the University of IllinoisInventor: Thomas G.H. Diekwisch
-
Publication number: 20130164271Abstract: The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them.Type: ApplicationFiled: May 27, 2011Publication date: June 27, 2013Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUG DER WISSENSCH E.V., HENRICH-PETTE-INSTITUT LEIBNZ-INSTITUT FOR EXPERIM VIROLOGIE-STIFTUNG BInventors: Joachim Hauber, Jan Chemnitz, Frank Buchholz, Janet Chusainow
-
Publication number: 20130136731Abstract: The present invention discloses novel hybrid proteins that have both plasminogen activator and anti-thrombotic properties, including clot specific action, that renders these as highly advantageous for the treatment of circulatory disorders involving fibrin clot formation due to underlying tissue damage in the blood vessels leading to myocardial infarction, strokes etc. Also disclosed are new proteins, and methods of obtaining the same, that help to dissolve blood clots by activating plasminogen in a plasmin or thrombin dependent manner and also inhibit both the activity and generation of thrombin through the intrinsic pathway of blood coagulation.Type: ApplicationFiled: August 5, 2011Publication date: May 30, 2013Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Neeraj Maheshwari, Girish Sahni
-
Publication number: 20130129697Abstract: Virion-associated peptidoglycan hydrolases have a potential as antimicrobial agents due to their ability to lyse Gram positive bacteria on contact. Full-length HydH5, a virion-associated peptidoglycan hydrolase from the Staphylococcus aureus bacteriophage vB_SauS-phi-IPLA88, and two truncated derivatives, containing only the CHAP domain, exhibited high lytic activity against live S. aureus cells. Three different fusion proteins were created and showed higher staphylolytic activity than the parental enzyme or its deletion construct. Parental and, fusion proteins lysed S. aureus cells in zymograms, plate lysis and turbidity reduction assays. In plate lysis assays, HydH5 and its derivative fusions lysed bovine and human S. aureus, S. aureus MRSA N315 strain, and human Staphylococcus epidermidis strains.Type: ApplicationFiled: November 17, 2011Publication date: May 23, 2013Inventors: David M. Donovan, Lorena Rodriguez Rubio, Beatriz Martinez Fernandez, Ana Rodriguez, Pilar Garcia Suarez
-
Publication number: 20130129700Abstract: The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution.Type: ApplicationFiled: November 30, 2012Publication date: May 23, 2013Applicant: Cydex Pharmaceuticals, Inc.Inventor: Cydex Pharmaceuticals, Inc.
-
Publication number: 20130121976Abstract: The present invention discloses strains of Lactobacillus and Streptococcus which have a capacity to degrade gliadin peptides involved in coeliac disease and which peptide degrading activity is stable under low pH and in the presence of mammalian digestive enzymes. These strains are suitable in a product for use in prevention and/or treatment of celiac disease.Type: ApplicationFiled: March 12, 2010Publication date: May 16, 2013Inventors: Agusti Montserrat Carreras, Montserrat Andreu Corominas, Daniel Ramon Vidal, Salvador Genoves Martinez, Esther Bataller Leiva
-
Patent number: 8440182Abstract: Provided herein are methods for treating a subject suffering from phenylketonuria by administering a phenylalanine hydroxylase (“PAH”) and/or a phenylalanine ammonia lyase (“PAL”) to the subject under conditions effective to deliver the phenylalanine 4-hydroxylase and/or PAL to the subject's small intestine. Also provided are methods for increasing the therapeutic activity of a phenylalanine 4-hydroxylase by thiolating the phenylalanine 4-hydroxylase. In addition, provided are oral dosage forms that include a phenylalanine 4-hydroxylase and/or a PAL and an enteric coating.Type: GrantFiled: November 20, 2009Date of Patent: May 14, 2013Assignee: The Board of Regents of the University of Texas SystemInventor: Reuben Matalon
-
Publication number: 20130095152Abstract: A therapeutic composition for the treatment of the symptoms of complex regional pain syndrome and a method for preparing the therapeutic composition is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of complex regional pain syndrome, or the likelihood of an individual to develop complex regional pain syndrome is disclosed.Type: ApplicationFiled: December 5, 2012Publication date: April 18, 2013Applicant: CUREMARK, LLCInventor: Curemark, LLC
-
Publication number: 20130089536Abstract: The present invention relates to a GCP II (glutamate carboxypeptidase II) mutant (K699S) having the activity of inhibiting glutamate production and the activity of cleavaging ?-amyloid, and to a pharmaceutical composition for the prevention and treatment of a disease selected from the group consisting of amyloidosis, Alzheimer's disease, Down syndrome accompanying Alzheimer's disease, stroke, dementia, Huntington's disease, Pick's disease, and Creutzfeldt-Jakob disease comprising the GCP II mutant (K699S) as an active ingredient. The GCP II (glutamate carboxypeptidase II) mutant (K699S) demonstrates not only excellent A? cleavage activity compared with the wild type GCP II but also excellent activity of inhibiting glutamate production, unlike the wild type GCP II, so that the mutant has been confirmed to have higher effect and stability than the wild type, suggesting that the GCP II mutant can be effectively used for the prevention or treatment of neurodegenerative diseases.Type: ApplicationFiled: October 8, 2012Publication date: April 11, 2013Applicant: KOREA CENTER FOR DISEASE CONTROL AND PREVENTIONInventor: Korea Center For Disease Control and Prevention
-
Publication number: 20130059001Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: ApplicationFiled: July 31, 2012Publication date: March 7, 2013Applicant: Curemark LLCInventor: Joan M. FALLON
-
Patent number: 8388953Abstract: The present invention provides a method of increasing cathepsin B-induced cleavage of amyloid-? (A?) peptide in a cell or tissue, the method generally involving contacting the cell or tissue with an agent that increases the level of cathepsin B in the cell or tissue. The present invention further provides variant cathepsin B polypeptides that are resistant to inhibition by a cysteine protease inhibitor; as well as nucleic acids encoding the variants, and host cells comprising the nucleic acids.Type: GrantFiled: June 29, 2010Date of Patent: March 5, 2013Assignee: The J. David Gladstone InstitutesInventors: Li Gan, Lennart Mucke, Erik Roberson, Sarah Mueller-Steiner
-
Patent number: 8383103Abstract: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, and cholecystitis for example.Type: GrantFiled: February 15, 2008Date of Patent: February 26, 2013Assignees: Allergan, Inc.Inventors: Franklin D. Gaylis, Andrew M. Blumenfeld
-
Publication number: 20130045196Abstract: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.Type: ApplicationFiled: December 8, 2010Publication date: February 21, 2013Applicant: HEALTHPOINT, LTD.Inventors: Lei Shi, Aleksa Jovanovic, Duncan Aust
-
Publication number: 20130045195Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.Type: ApplicationFiled: March 30, 2011Publication date: February 21, 2013Applicant: ALVINE PHARMACEUTICALS, INC.Inventor: Pawan Kumar
-
Publication number: 20130039897Abstract: The disclosure relates to compositions including dipeptidyl peptidase-IV (DPPIV) as well as compositions including an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a Dictyostelium autocrine proliferation repressor A (AprA) region. The disclosure also relates to a method of reducing the number of neutrophils in a body region by administering a DPPIV composition to the body region in an amount and for a time sufficient to suppress neutrophil movement into the body region or enhancing neutrophil movement out of the body region. In particular, it relates to a method of reducing the number of neutrophils in a body region suffering from an acute injury or from a chronic or long-term disease. Further, the disclosure relates to a method of increasing the number of neutrophils in a body region by administering an anti-DPPIV antibody operable to bind a DPPIV region structurally homologous to a Dictyostelium AprA region.Type: ApplicationFiled: August 10, 2012Publication date: February 14, 2013Applicant: The Texas A&M University SystemInventors: Richard Gomer, Jonathan Phillips, Sarah Herlihy, Anu S. Maharjan, Darrell Pilling
-
Publication number: 20130034535Abstract: Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics.Type: ApplicationFiled: August 13, 2012Publication date: February 7, 2013Applicant: PIVOTAL THERAPEUTICS INC.Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar SHAIKH, Jason YANTHA, Valerie SCHINI-KERTH
-
Patent number: 8367060Abstract: The present invention relates to a composition and a method for the treatment of liver dysfunction which contains administration of a composition containing arazyme as an active ingredient, more precisely arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects the liver by inhibiting liver injury around the central vein region. Therefore, the arazyme of the invention can be effectively used as a composition for the treatment of liver dysfunction.Type: GrantFiled: September 16, 2011Date of Patent: February 5, 2013Assignee: Insect Biotech Co., Ltd.Inventors: Ho-Yong Park, Kwang-Hee Son, Dong-Ha Shin, Kyu-Shik Jeong
-
Publication number: 20130028884Abstract: There is provided a skin treatment composition for oral or topical administration and a method for skin treatment. The composition comprises a chelating agent and at least one protease. The composition helps to remove hemosiderin that causes staining of skin on a bruised area and reduces inflammation and pain.Type: ApplicationFiled: October 9, 2012Publication date: January 31, 2013Applicant: SCARGUARD LABS, LLC.Inventor: JOEL R. STUDIN
-
Publication number: 20130017186Abstract: Provided are viscous and adherent food-safe antimicrobial compositions, and methods for using same in the immediate and residual decontamination of microbial-contaminated substrate surfaces, in reducing or precluding cutting implement-mediated transfer of surface contamination during cutting operations in the food industry, and for reducing or preventing transfer of contamination from contaminated surfaces in the food and pharmaceutical industries. Adherent antimicrobial protective layers are formed on substrate surfaces (e.g., processing equipment and utensils), providing a barrier (e.g., chemical and/or physical) to the passage or transport of microbial contamination between and among surfaces.Type: ApplicationFiled: July 17, 2012Publication date: January 17, 2013Applicant: Institute for Environmental Health, Inc.Inventor: Mansour Samadpour
-
Publication number: 20130011446Abstract: The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (w/w), the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (w/w) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35.Type: ApplicationFiled: September 13, 2012Publication date: January 10, 2013Inventor: Carl Alexander DePaula
-
Publication number: 20120321611Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: ApplicationFiled: July 2, 2012Publication date: December 20, 2012Applicants: SCHEPENS EYE RESEARCH INSTITUTE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20120321581Abstract: Disclosed herein are compositions and methods to target enzymatic peracid production to a target surface. The peracid benefit agent produced by the targeted perhydrolytic enzyme can be use for a variety of applications such as bleaching, whitening, disinfecting, destaining, deodorizing, and combinations thereof. Specifically, a fusion protein comprising a perhydrolytic enzyme and at least one peptidic component having affinity for a target surface (excluding body surfaces and oral care surfaces) is used in combination with a suitable substrate and a source of peroxygen to enzymatically produce a peracid on or near the surface of the target material. In a preferred aspect, the target surface is a cellulosic material.Type: ApplicationFiled: December 19, 2011Publication date: December 20, 2012Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: Robert DiCosimo, Scott D. Cunningham, Stephen R. Fahnestock, Tanja Maria Gruber, Mark S. Payne, Pierre E. Rouviere, Linda Jane Solomon, Hong Wang
-
Publication number: 20120318262Abstract: The present invention concerns a pyrvinium compound or salt or an analog thereof for the treatment of wounds. The present invention also concerns devices for delivering a pyrvinium compound or salt or an analog thereof for a wound.Type: ApplicationFiled: March 21, 2012Publication date: December 20, 2012Inventors: Ethan Lee, Pampee Paul Young
-
Publication number: 20120315263Abstract: The invention provides a method and compositions for treating a subject with a lysosomal storage disease such as gaucher disease, by administering to a subject with a lysosomal storage disease a therapeutically effective amount of composition comprising at least one of a protease or peptidase in an amount sufficient to ameliorate, reduce or improve at least one symptom of the disease. The invention also provides dietary supplements for subjects having lysosomal storage diseases.Type: ApplicationFiled: June 10, 2011Publication date: December 13, 2012Inventor: Stephen F. Olmstead
-
Publication number: 20120308644Abstract: Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral, gastrointestinal and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.Type: ApplicationFiled: August 6, 2012Publication date: December 6, 2012Inventors: Philip James Bromley, Lee Nickols Huang
-
Publication number: 20120301458Abstract: The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereofType: ApplicationFiled: July 27, 2010Publication date: November 29, 2012Applicant: Auspex Pharmaceuticals, Inc.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Patent number: 8318158Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: GrantFiled: October 12, 2011Date of Patent: November 27, 2012Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Patent number: 8309341Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or a group of formula COR4, or R1 represents a group of formula (A): R2 represents a group of formula NR5R6, or R2 represents a nitrogen-containing heterocyclic group, an aryl group or a heteroaryl group, R3 represents a hydrogen atom or an alkyl group, m represents an integer between 1 and 6 inclusive, n represents 0, 1 or 2, their optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating and/or preventing thrombotic events.Type: GrantFiled: June 25, 2010Date of Patent: November 13, 2012Assignees: Les Laboratories Server, L'Institut National des Sciences Appliquées de Rouen, Le Centre National de la Recherche Scientifique, L'Universite de RouenInventors: Philippe Gloanec, Guillaume De Nanteuil, Jean-Gilles Parmentier, Anne-Françoise Guillouzic, Tony Verbeuren, Alain Rupin, Philippe Mennecier, Marie-Odile Vallez, Jean-Charles Quirion, Philippe Jubault, Nicolas Boyer
-
Patent number: 8303944Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: February 13, 2008Date of Patent: November 6, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Patent number: 8293230Abstract: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.Type: GrantFiled: September 6, 2005Date of Patent: October 23, 2012Assignee: TOXOGEN GmbHInventor: Andreas Rummel